MiR-214 induces cell survival and cisplatin resistance by targeting PTEN in ovarian cancer [22] while MiR-214 targets the β-catenin pathway to suppress invasion, stem-like traits, and the recurrence of human hepatocellular carcinoma [23]. Here, PTEN is linked to ovarian carcinoma.